The joining of Northway Biotech to a Lithuanian science and business consortium collaborating with the Massachusetts Institute of Technology (MIT, USA) marks a new stage in international life sciences cooperation. For the first time, industrial experience in the development of biological medicines is being systematically combined with the world-leading expertise of MIT and the academic competence of Lithuania.
Hørsholm, Denmark, 28 January 2026 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of vaccine candidates targeting infectious diseases and cancer, today announced that it has selected Northway Biotech as its cGMP contract development and manufacturing organization (CDMO) for its Nipah virus vaccine candidate. The program is being developed as part of an EU-funded Horizon Europe consortium project, supported under the European Union’s competitive research and innovation framework and addressing a pathogen that has recently caused renewed outbreaks in South Asia.
Vilnius, Lithuania, October 14, 2025 – Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO), is delighted to announce its recognition as a winner of the Outsourced Pharma and Life Science Connect 2025 CDMO Leadership Awards Europe in the Biologics category. This marks the company’s second recognition this year, following its earlier achievement in the Global Biologics CDMO category.
At this year’s Life Sciences Baltics 2025 in Vilnius, Korean Pharm-Edaily (팜이데일리), a leading South Korean life sciences publication, highlighted Lithuania’s rapidly growing biotech ecosystem, with Northway Biotech recognized for its biomanufacturing expertise within the region.
Boston, MA and Vilnius, Lithuania, July 29, 2025 - Diorasis Therapeutics ("DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic partnership with Northway Biotech ("NBT"), a contract development and manufacturing organization (CDMO), to establish a scalable cGMP production process for DTx’s lead AAV-based gene therapy candidate for open angle glaucoma.
• Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin • Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action Martinsried, Germany and Vilnius, Lithuania, July 15, 2025 - AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec’s lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).
Waltham, MA, May 21, 2025 - Northway Biotech, Inc. (“Northway Biotech”), an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), and Kaida BioPharma (“Kaida” or the “Company”), an early-stage pharma company dedicated to advancing targeted anti-cancer therapies to address hormone-driven cancers affecting women, today announced they have entered into a manufacturing agreement for the production of Kaida’s lead product candidate, KAD101.
Vilnius, Lithuania - May 5, 2025 - Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), today announced the expansion of its protein-based and gene therapy service offerings with the addition of Viral Clearance Studies (VCS) capabilities. This strategic growth follows the opening of Northway Biotech’s new Gene Therapy Center with dedicated cGMP facilities for virus-related projects.
Vilnius, Lithuania, April 24, 2025 – Northway Biotech is proud to share that it has been named Investor of the Year at the 2024 Investors’ Forum Awards. The award recognizes the company’s contribution to the growth of Lithuania’s biotechnology sector and the strengthening of its business environment, led by its CEO, Prof. Vladas Algirdas Bumelis.
Vilnius, Lithuania, March 20, 2025 – Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO), is proud to be recognized as winners of the Outsourced Pharma and Life Science Connect 2025 CDMO Leadership Awards in the Global Biologics CDMO category.
Zug, Switzerland, and Vilnius, Lithuania, March 4, 2025 – Micreos Pharmaceuticals AG ("Micreos"), a preclinical-stage biopharmaceutical company, specializing in developing Engineered Endolysin therapies to target harmful pathogens that cause disease aggravation, has entered into a strategic partnership with Northway Biotech ("NBT"), a Contract Development and Manufacturing Organization (CDMO) to develop scalable cGMP production processes for Micreos' biologic therapeutic MEndoB, which is the first-in-class dual-active domain targeted medicine that will enter the clinic in the coming months as an investigational therapeutic to treat Atopic Dermatitis.
Erlangen, Germany and Vilnius, Lithuania, February 4, 2023 – Mallia Therapeutics ("Mallia"), a biopharmaceutical company developing novel treatments for hair loss, and Northway Biotech ("NBT"), a biologics Contract Development and Manufacturing Organization (CDMO), have announced a partnership for the development of the production process and manufacturing of Mallia's soluble CD83 protein (sCD83), a treatment aimed at promoting hair follicle formation and growth.
Vladas Algirdas Bumelis, CEO of Northway Biotech, has been honored with the LRT Year Award for Business Leadership.This award recognizes his contributions to the biotechnology sector, particularly in advancing Lithuania’s position in life sciences. It highlights his role in the development of the BIO CITY biotechnology hub and the establishment of the Gene Therapy Centre in Vilnius.
Northway Biotech is proud to announce that our CEO, Prof. Vladas Algirdas Bumelis, has been honored with the Global Lithuanian Award for Lithuania’s Breakthrough Innovation Worldwide at the 2024 Global Lithuanian Awards. This prestigious recognition celebrates his exceptional contributions to enhancing Lithuania’s global reputation, particularly in the field of biotechnology.
Celltechna, a Lithuanian company providing advanced gene therapy drug development and manufacturing services to pharmaceutical companies in Europe and the US, opened the first and only gene therapy centre in the Baltic States in Vilnius on Thursday. The expansion of the biotechnology city BIO CITY and the move into a new area, where two additional production centres are to be established, were also presented. This three-part project, consisting of 9 biopharmaceutical centres, is expected to attract around €7 billion in investment over the next decade.
Northway Biotech is proud to announce that our CEO, Prof. Vladas Algirdas Bumelis, has been honored with the prestigious Business Breakthrough Award at the 2024 Life Sciences Progress Awards. This recognition underscores his visionary leadership in developing BIO CITY, an ambitious project set to become Europe’s largest biotechnology campus and highlights his significant contributions to the growth of Lithuania's life sciences sector.
On Thursday evening, around 100 guests gathered at the Sapiehas Palace in Vilnius to celebrate the 20th birthday of the „Northway Group“. Today, the group crosses not only national borders but also the ocean that separates continents – „Northway“ successfully develops science and business projects in Lithuania, Latvia, the United Kingdom, and the USA.
The 40th anniversary of the Lithuanian biopharmaceutical industry and science was marked on Monday with the opening of the Lithuanian Biotechnology Museum in the village of Savaitiskes in Trakai District. The founder of the museum, Professor Vladas Algirdas Bumelis, has accumulated a collection of unique instruments and equipment reflecting the development of life sciences in Lithuania over 50 years of activity.
The Nordic Investment Bank (NIB), Citadele bank and the Lithuanian biopharmaceutical company UAB Celltechna signed a ten-year financing agreement of EUR 37 million for a gene therapy product facility in Vilnius. NIB will provide a EUR 22.5 million loan, and Citadele will extend a EUR 14.5 million loan for the project.
Biologics have great potential for the treatment of many diseases, especially regarding unmet medical needs, due to their target specificity. Moreover, even for diseases where small molecule therapies already exist, there is potential for biologics to provide a more effective solution. However, developing a biologic can often be more challenging compared to their small molecule counterparts. They are more likely to become unstable, have more complex structures, and therefore require more specialized development and manufacturing processes, next to the fact that living organisms are involved in the process which leads to further volatility. It is important to work with a contract development and manufacturing organization (CDMO) that can match these requirements, accommodate challenges in a flexible way and keep the development process moving towards commercialization.
